Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) and InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
Collegium Pharmaceutical has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Valuation and Earnings
This table compares Collegium Pharmaceutical and InMed Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Collegium Pharmaceutical | $815.19 million | 0.97 | $62.87 million | $1.00 | 25.32 |
| InMed Pharmaceuticals | $4.94 million | 9.72 | -$12.56 million | ($1.64) | -8.84 |
Collegium Pharmaceutical has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
20.1% of InMed Pharmaceuticals shares are held by institutional investors. 1.8% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Collegium Pharmaceutical and InMed Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Collegium Pharmaceutical | 0 | 2 | 7 | 1 | 2.90 |
| InMed Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
Collegium Pharmaceutical presently has a consensus target price of $44.88, suggesting a potential upside of 77.23%. InMed Pharmaceuticals has a consensus target price of $42.00, suggesting a potential upside of 189.66%. Given InMed Pharmaceuticals’ higher probable upside, analysts plainly believe InMed Pharmaceuticals is more favorable than Collegium Pharmaceutical.
Profitability
This table compares Collegium Pharmaceutical and InMed Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Collegium Pharmaceutical | 4.68% | 85.14% | 13.80% |
| InMed Pharmaceuticals | N/A | -282.17% | -187.15% |
Summary
Collegium Pharmaceutical beats InMed Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
About Collegium Pharmaceutical
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a Canada-based biotechnology company focused on developing pharmaceutical therapies that target the endocannabinoid system. The company’s research uses rare cannabinoids and cannabinoid analogs to address diseases with significant unmet medical needs, with an emphasis on neurological, ophthalmic and dermatological conditions. InMed’s pipeline has included INM-901, an investigational program being developed for Alzheimer’s disease, as well as earlier programs targeting eye diseases such as glaucoma and age-related macular degeneration and the rare skin disorder epidermolysis bullosa.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
